IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.679,29 +331,78 (+0,59%)
ImmunoPrecise Antibodies Ltd. (IPA)
Después del cierre:
ImmunoPrecise Antibodies Ltd.
3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada
250-483-0308
https://www.ipatherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 102
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | CEO, President & Non-Independent Director | 1,02M | N/A | N/A |
| Dr. Ilse Roodink | Chief Scientific Officer & Interim General Manager of IPA Europe, Oss | 275,4k | N/A | N/A |
| Ms. Kristin Taylor CPA, M.B.A. | Chief Financial Officer | N/A | N/A | N/A |
| Mr. David E. Orton | Chief Operating Officer | N/A | N/A | N/A |
| Dr. Roland Romijn | Head of General Operations of the Utrecht site of IPA (Europe) | N/A | N/A | N/A |
Descripción
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.
Gobierno corporativo
El ISS Governance QualityScore de ImmunoPrecise Antibodies Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
